Janus Henderson Group PLC Purchases 324,614 Shares of Immunome, Inc. (NASDAQ:IMNM)

Janus Henderson Group PLC boosted its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 10.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,488,121 shares of the company's stock after buying an additional 324,614 shares during the period. Janus Henderson Group PLC owned 5.81% of Immunome worth $50,971,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IMNM. Quest Partners LLC acquired a new stake in Immunome during the second quarter valued at $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Immunome in the second quarter valued at about $97,000. Arizona State Retirement System raised its holdings in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock worth $131,000 after buying an additional 918 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock valued at $194,000 after acquiring an additional 4,129 shares during the period. Finally, Sequoia Financial Advisors LLC acquired a new position in Immunome in the second quarter valued at about $206,000. 44.58% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Clay B. Siegall acquired 66,057 shares of Immunome stock in a transaction on Thursday, November 21st. The stock was acquired at an average cost of $9.54 per share, with a total value of $630,183.78. Following the transaction, the chief executive officer now owns 485,693 shares of the company's stock, valued at approximately $4,633,511.22. This trade represents a 15.74 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Max Rosett sold 14,380 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total value of $230,223.80. Following the sale, the chief financial officer now directly owns 47,476 shares of the company's stock, valued at $760,090.76. The trade was a 23.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 102,862 shares of company stock worth $978,045. Company insiders own 8.60% of the company's stock.

Immunome Price Performance

Shares of Immunome stock traded up $1.03 during midday trading on Friday, reaching $13.73. The company had a trading volume of 460,929 shares, compared to its average volume of 780,945. The stock has a fifty day moving average price of $12.24 and a 200 day moving average price of $13.48. Immunome, Inc. has a fifty-two week low of $6.93 and a fifty-two week high of $30.96. The firm has a market cap of $856.99 million, a PE ratio of -1.57 and a beta of 1.83.

Analysts Set New Price Targets

Several research analysts have issued reports on IMNM shares. Wedbush reaffirmed an "outperform" rating and set a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Piper Sandler lowered their price objective on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Finally, Stephens assumed coverage on shares of Immunome in a report on Friday, November 8th. They issued an "overweight" rating and a $30.00 price target for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has a consensus rating of "Buy" and an average price target of $28.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.